TSBX — Turnstone Biologics Balance Sheet
0.000.00%
- $8.10m
- -$20.83m
Annual balance sheet for Turnstone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 161 | 82.1 | 94.8 | 28.9 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 6.71 | 8.73 | 0.194 | 0 |
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 177 | 98 | 103 | 34.2 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 9.37 | 14.4 | 9.12 | 5.11 |
Other Long Term Assets | ||||
Total Assets | 187 | 115 | 113 | 40.1 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 55 | 34.8 | 12 | 8.2 |
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 97.3 | 44.5 | 14.1 | 8.67 |
Redeemable Preferred Stock | ||||
Non Redeemable Preferred Stock | ||||
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | 89.9 | 70.5 | 98.7 | 31.5 |
Total Liabilities & Shareholders' Equity | 187 | 115 | 113 | 40.1 |
Total Common Shares Outstanding |